Physician profile
Junfeng Wang
NPI 1154533412
$2,578.81
in general payments reported to CMS, 2019-2025
36 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $170 · 2021: $233 · 2022: $712 · 2023: $1,021 · 2024: $21.74 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $423.64 | 2019-2025 | Carvykti, Rybrevant, Erleada |
| Amgen INC. | $264.80 | 2019-2023 | Kyprolis, Lumakras, Blincyto |
| Glaxosmithkline, LLC. | $207.39 | 2022-2023 | Jemperli, Zejula |
| E.R. Squibb & Sons, L.L.C. | $187.09 | 2019-2023 | Opdivo, Opdualag |
| Celgene Corporation | $173.23 | 2019-2023 | Pomalyst, Reblozyl |
| Seagen INC. | $118.90 | 2020-2023 | Tukysa |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $96.24 | 2022-2023 | Imbruvica |
| Lilly USA, LLC | $82.24 | 2021-2023 | |
| Myriad Genetic Laboratories, INC. | $76.93 | 2021-2024 | Precisetumor, Myrisk |
| Novartis Pharmaceuticals Corporation | $76.03 | 2019-2025 | |
| Pfizer INC. | $61.68 | 2023 | |
| Merck Sharp & Dohme LLC | $56.14 | 2019-2023 | Lynparza, Keytruda, Welireg |
| Genentech USA, INC. | $53.17 | 2019-2023 | Columvi, Lunsumio, Polivy |
| Blueprint Medicines Corporation | $51.89 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $51.84 | 2020-2023 | |
| Kite Pharma, INC. | $46.23 | 2022-2023 | |
| Sobi, INC | $42.46 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $38.85 | 2023 | Lynparza, Imfinzi |
| Tolmar Pharmaceuticals, INC. | $35.45 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.51 | 2023 | Gilotrif |
| Regeneron Healthcare Solutions, INC. | $29.18 | 2021 | |
| Tempus Ai, INC | $27.98 | 2025 | Xt Cdx |
| Exelixis INC. | $26.11 | 2022 | |
| Sumitomo Pharma America, INC. | $24.05 | 2023 | Orgovyx |
| Emd Serono, INC. | $23.64 | 2023 | Bavencio |
| Agios Pharmaceuticals, INC. | $22.67 | 2019 | |
| Cti Biopharma Corp. | $21.20 | 2022 | |
| Daiichi Sankyo INC. | $19.69 | 2023 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $18.67 | 2019 | |
| Dova Pharmaceuticals | $18.41 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2023 | |
| Eusa Pharma (US) LLC | $15.24 | 2022 | |
| Astellas Pharma US INC | $14.98 | 2023 | Xospata |
| Servier Pharmaceuticals LLC | $13.29 | 2022 | |
| Myovant Sciences INC. | $13.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junfeng Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.